Recombinant Anti-Tet2 antibody [EPR20546-135] (ab213369)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR20546-135] to Tet2
- Suitable for: WB
- Knockout validated
- Reacts with: Mouse
Related conjugates and formulations
Overview
-
Product name
Anti-Tet2 antibody [EPR20546-135]
See all Tet2 primary antibodies -
Description
Rabbit monoclonal [EPR20546-135] to Tet2 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt (Intra),ICC,IHC-P or IP -
Species reactivity
Reacts with: Mouse -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: WT mESCs, RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage), whole cell lysate; Wild-type B-cell lysate.
-
General notes
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR20546-135 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab213369 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/1000. Predicted molecular weight: 223 kDa.
|
Notes |
---|
WB
1/1000. Predicted molecular weight: 223 kDa. |
Target
-
Function
Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. -
Tissue specificity
Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes. -
Involvement in disease
Note=TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites.
Defects in TET2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
Note=TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen.
Note=TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. -
Sequence similarities
Belongs to the TET family. - Information by UniProt
-
Database links
- Entrez Gene: 214133 Mouse
- SwissProt: Q4JK59 Mouse
- Unigene: 347816 Mouse
-
Alternative names
- FLJ20032 antibody
- KIAA1546 antibody
- MDS antibody
see all
Images
-
Western blot - Anti-Tet2 antibody [EPR20546-135] (ab213369)Image courtesy of Dr Hugo Sepulveda in Prof Anjana Rao’s laboratory (La Jolla Institute for Immunology)All lanes : Anti-Tet2 antibody [EPR20546-135] (ab213369) at 1/2000 dilution
Lane 1 : Wild-Type Mouse embryonic stem cells (mESCs)
Lane 2 : Tet1/2/3 Triple-Knockout (Tet-TKOs) Mouse embryonic stem cells (mESCs)
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Rat anti-mouse HRP Conjugate at 1/4000 dilution
Predicted band size: 223 kDa
Observed band size: 250 kDa why is the actual band size different from the predicted?
Additional bands at: 65 kDa (possible non-specific binding)
Exposure time: 10 secondsBlocking buffer: 5% milk.
-
Western blot - Anti-Tet2 antibody [EPR20546-135] (ab213369)Image courtesy of Dr Hugo Sepulveda in Prof Anjana Rao’s laboratory (La Jolla Institute for Immunology)All lanes : Anti-Tet2 antibody [EPR20546-135] (ab213369) at 1/1000 dilution
Lane 1 : Wild-type B-cell lysate
Lane 2 : Tet2/3 DKO B-cell lysate
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)
Predicted band size: 223 kDa
Observed band size: 257 kDa why is the actual band size different from the predicted?
Exposure time: 60 secondsBlocking and Diluting buffer: 5% NFDM/TBST
This western was done using lysates from a Tet2/3 DKO B-cell model developed by Dr Vipul Shukla and Dr Chan-Wang Lio, in Prof Anjana Rao’s lab.
-
Anti-Tet2 antibody [EPR20546-135] (ab213369) at 1/1000 dilution + RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage), whole cell lysate at 20 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)
Predicted band size: 223 kDa
Observed band size: 257 kDa why is the actual band size different from the predicted?Blocking and Diluting buffer: 5% NFDM/TBST
Exposure time: 3 minutes
This blot was developed using a higher sensitivity ECL substrate.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (0)
ab213369 has not yet been referenced specifically in any publications.